Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMYPQT4)

Drug Name
4SCAR19 and 4SCAR123 Drug Info
Indication
Disease Entry ICD 11 Status REF
B-cell lymphoma 2A86 Phase 1/2 [1]
Cross-matching ID
TTD Drug ID
DMYPQT4

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
B-lymphocyte surface antigen B4 (CD19) TTW640A CD19_HUMAN CAR-T-Cell-Therapy(Dual specific) [1]
Interleukin 3 receptor alpha (IL3RA) TTENHJ0 IL3RA_HUMAN CAR-T-Cell-Therapy(Dual specific) [1]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
B-lymphocyte surface antigen B4 (CD19) DTT CD19 5.758 6.211 6.083 5.396
Interleukin 3 receptor alpha (IL3RA) DTT IL3RA 1.807 3.926 2.678 3.573
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease B-cell lymphoma
ICD Disease Classification 2A86
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
B-lymphocyte surface antigen B4 (CD19) DTT CD19 2.33E-24 -1.06 -1.33
Interleukin 3 receptor alpha (IL3RA) DTT IL3RA 8.71E-54 0.98 2.64
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT03125577) Combination CAR-T Cell Therapy Targeting Hematological Malignancies